Development of novel chimeric antigen receptor-expressing T cells promoting immune cell infiltration and survival in the tumor tissue
Project/Area Number |
26830107
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor therapeutics
|
Research Institution | Yamaguchi University |
Principal Investigator |
ADACHI Keishi 山口大学, 医学(系)研究科(研究院), 助教 (40598611)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 次世代型キメラ抗原受容体発現T細胞 / サイトカイン / ケモカイン / がん / 抗がん効果 / キメラ抗原受容体 / IL-7 / CCL19 / 抗がん作用 |
Outline of Final Research Achievements |
The goal of this project is to generate a novel cancer therapy using the next generation chimeric antigen receptor (CAR)-expressing T cell that exerts anti-cancer effect more effectively than the conventional one. So far, the following results have been obtained; 1) The next generation CAR-T cell that concomitantly expresses CAR specific to a tumor antigen, a cytokine committing to T cell survival, and a chemokine inducing migration of T cells was generated. 2) The next generation CAR-T cells exerted more potent anti-tumor effects than the conventional one in several murine tumor models. 3) Molecular mechanisms underlying the potent tumoricidal efficacy of the next generation CAR-T cells were elucidated.
|
Report
(5 results)
Research Products
(4 results)